Debra BorchardtNovember 8, 2022Tag: Corbus Pharmaceutical
Debra BorchardtNovember 8, 2022
Debra BorchardtMarch 15, 2021
Endocannabinoid drug development company Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported financial results for the fourth quarter and year-end 2020. The company said that revenue from awards and licenses was $700,000 for the quarter ending December 31, 2020, versus $2.6 million in the same time period in 2019. Corbus delivered a net loss of approximately […]
Debra BorchardtOctober 23, 2020Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported that its drug, Lenabasum did not meet its primary efficacy endpoint of reducing the rate of PEx. Lenabasum is a novel, oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2) and resolves inflammation and limits fibrosis in animal and human models […]
William SumnerJanuary 31, 2018
Research Driven Investing (RDI) has initiated coverage on Corbus Pharmaceuticals Holdings, Inc. (CRBP) with a Neutral rating. Corbus Pharmaceuticals late-stage stage clinical pharmaceutical company that is focused on the development and commercialization of unique medicines aimed at treating inflammatory and fibrotic diseases. Based in Norwood, Massachusetts, the company’s lead product is JBT-101, an oral endocannabinoid-mimetic […]
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.